ReviewJournal of ovarian research2026
Progress in research on the effects of Platelet-Rich Plasma (PRP) ovarian injection on early ovarian reserve dysfunction and premature ovarian insufficiency.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Platelet-rich plasma and folliculogenesis: a systematic mechanistic review and computational pathway analysis.Frontiers in reproductive health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly ovarian reserve decline (EORD) and premature ovarian insufficiency (POI) pose major challenges in reproductive medicine, as few interventions can truly restore ovarian function or fertility. Conventional hormone replacement therapy alleviates symptoms but fails to rejuvenate the ovarian microenvironment, prompting growing interest in regenerative approaches such as platelet-rich plasma (PRP) therapy.
objectiveThis review critically evaluates the therapeutic potential of intraovarian PRP injection for women with EORD and POI, integrating mechanistic insights, preclinical findings, and clinical evidence to clarify its biological rationale and translational challenges.
methodsWe systematically synthesized literature on PRP composition, preparation methods, and reproductive applications. Mechanistic data from animal and cell models were combined with evidence from clinical studies to elucidate how PRP modulates angiogenesis, follicular activation, apoptosis, and immune regulation through pathways such as PI3K/Akt, MAPK, and mTOR.
resultsPRP delivers a rich concentration of growth factors, cytokines, and extracellular vesicles that orchestrate angiogenesis, suppress apoptosis, and remodel the ovarian niche. Preclinical and early clinical studies consistently report improved ovarian reserve markers, partial hormonal recovery, and resumption of menses in some patients, although heterogeneity in protocols and limited sample sizes hinder definitive conclusions.
conclusionIntraovarian PRP represents a biologically plausible and minimally invasive regenerative strategy for ovarian rejuvenation. Future research should prioritize the development of standardized preparation protocols, biomarker-guided patient selection, and large multicenter randomized trials to confirm its safety, efficacy, and long-term clinical value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.